Akoya Biosciences, Inc. (NASDAQ:AKYA) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lessened its stake in Akoya Biosciences, Inc. (NASDAQ:AKYA) by 64.2% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 63,002 shares of the company’s stock after selling 112,886 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Akoya Biosciences were worth $171,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AKYA. GSA Capital Partners LLP grew its stake in shares of Akoya Biosciences by 87.4% in the 3rd quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock valued at $845,000 after purchasing an additional 144,903 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Akoya Biosciences by 16.2% during the second quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock worth $158,000 after purchasing an additional 9,429 shares during the period. Finally, Regal Investment Advisors LLC lifted its holdings in shares of Akoya Biosciences by 64.3% during the second quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock worth $44,000 after purchasing an additional 7,340 shares during the period. 79.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on AKYA. Piper Sandler reissued an “overweight” rating and issued a $3.00 price objective (down from $4.00) on shares of Akoya Biosciences in a research note on Tuesday, November 19th. Craig Hallum lowered shares of Akoya Biosciences from a “buy” rating to a “hold” rating and dropped their price target for the stock from $7.00 to $5.00 in a research note on Friday, November 15th. Finally, Canaccord Genuity Group cut their price target on shares of Akoya Biosciences from $6.00 to $3.50 and set a “buy” rating for the company in a report on Friday, November 15th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $5.43.

Akoya Biosciences Stock Performance

NASDAQ:AKYA opened at $2.55 on Friday. The firm’s fifty day simple moving average is $2.64 and its 200-day simple moving average is $2.50. The company has a quick ratio of 1.85, a current ratio of 2.75 and a debt-to-equity ratio of 5.62. The stock has a market cap of $126.39 million, a PE ratio of -2.16 and a beta of 1.22. Akoya Biosciences, Inc. has a fifty-two week low of $1.88 and a fifty-two week high of $6.31.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.